CJC-1295 + Ipamorelin Blend 10mg (No DAC)

Name: CJC-1295 + Ipamorelin Blend 10mg (No DAC)
SKU: 41
Price: 73.00 USD
Availability: InStock

$73.00

A dual growth-hormone-secretagogue research blend pairing the GHRH analog CJC-1295 (no DAC / modified GRF 1-29) with the selective GHRP Ipamorelin, co-lyophilized in one vial for in-vitro endocrinology research.

Tested by Freedom Diagnostics TestingHPLC purity + LC-MS identityLot-matched COA on-site

For research use only. This product is a laboratory research chemical. It is not for human or veterinary use, not a drug, supplement, or food, and not intended to diagnose, treat, cure, or prevent any disease. Sold only to qualified researchers and institutions.

Category: Growth Hormone Peptides

Description
Reviews (0)

What is CJC-1295 + Ipamorelin?

CJC-1295 + Ipamorelin (No DAC) is a co-lyophilized blend of two synthetic peptides that act as a dual growth-hormone secretagogue system. CJC-1295 (no DAC) is a modified GRF(1-29), a growth-hormone-releasing-hormone (GHRH) analog that binds the GHRH receptor on pituitary somatotrophs, while Ipamorelin is a selective growth-hormone-releasing peptide (GHRP) that binds the ghrelin receptor (GHS-R1a). Because the two peptides engage different receptors on the same cells, laboratories use the blend as a reference GHRH-plus-GHRP combination for studying synergistic GH release.

Research areas where laboratories buy this blend for in vitro work include GHRH-R and GHS-R1a co-activation studies on pituitary somatotrophs, GH-release synergy experiments comparing single versus dual secretagogues, cAMP and calcium-mobilization signaling assays, and selectivity profiling against ACTH, cortisol, and prolactin readouts. Neither component is an FDA-approved drug.

Every lot, independently verified

Independently third-party tested and matched to the lot ID printed on your vial. Values below are from the latest released lot.

≥99%

HPLC-UV Purity

Passed full QC panel

independent third-party lab (Freedom Diagnostics Testing) accredited lab

Per-lot HPLC-UV + LC-MS · independent ISO 17025 lab

Lot details

ProductCJC-1295 + Ipamorelin (No DAC)

LotPer-batch on COA

AppearanceWhite lyophilized powder

ReleaseFull QC panel per lot

DocumentationLot-matched COA

Full QC panel · ISO 170256 assays

Purity (HPLC-UV)≥99% per lot ✓

Identity (LC-MS)CJC-1295 / Ipamorelin ✓

HPLC conformity (2×)Confirmed ✓

Heavy metals (ICP-MS)Not Detected ✓

SterilityNo Growth ✓

Endotoxin (USP <85>)Within limits ✓

Compound information

Chemical & structural reference data — specifications, molecular profile and handling.

Product Specifications

CompoundCJC-1295 (no DAC) + Ipamorelin dual GH-secretagogue blend

Vial sizeCo-lyophilized blend vial

Purity≥99% by HPLC (each component)

Identity confirmationMass spectrometry

FormCo-lyophilized white powder

Appearance after reconstitutionClear, colorless solution

ManufacturingSynthesized and lyophilized in the United States

Quality testingIndependent independent third-party laboratory release

Molecular Profile

CompositionCJC-1295 (no DAC) + Ipamorelin

CJC-1295Modified GRF(1-29) · GHRH analog

IpamorelinAib-His-D-2-Nal-D-Phe-Lys-NH₂ · GHRP

ReceptorsGHRH-R + GHS-R1a

FormCo-lyophilized sterile cake

CAS · Ipamorelin170851-70-4

Storage & Handling

AppearanceWhite lyophilized powder

SolubilitySterile or bacteriostatic water · neutral pH

Storage · powder−20 °C, desiccated, dark (−80 °C long-term)

In solution2–8 °C; aliquot & freeze, avoid freeze-thaw

CJC-1295 + Ipamorelin Mechanism of Action

CJC-1295 (no DAC) binds the GHRH receptor on pituitary somatotrophs, signaling through Gαs / cAMP to stimulate GH synthesis and release.
Ipamorelin binds the ghrelin receptor (GHS-R1a), acting through Gq/PLC and calcium mobilization on the same somatotrophs.
The two receptor mechanisms are complementary — GHRH-R and GHS-R1a agonism synergize on GH release in paired secretagogue studies.
Ipamorelin’s selectivity keeps ACTH, cortisol, and prolactin readouts largely unaffected.
The ‘no DAC’ CJC-1295 (modified GRF 1-29) lacks the drug-affinity-complex, giving a shorter-acting GHRH profile than DAC versions.
Used as the reference GHRH+GHRP dual-secretagogue tool combination.

CJC-1295 + Ipamorelin Research Applications

GHRH-R and GHS-R1a co-activation studies on pituitary somatotrophs.
GH-release synergy experiments comparing single versus dual secretagogues.
cAMP and calcium-mobilization signaling assays.
Selectivity profiling against ACTH/cortisol/prolactin readouts.
Pulsatile GH-secretion modeling under defined conditions.
Structure-activity studies of GHRH-analog plus GHRP combinations.

Why Buy CJC-1295 + Ipamorelin from Koi Peptides?

Every batch of Koi CJC-1295 + Ipamorelin is synthesized and lyophilized in the United States, then released against independent third-party laboratory (Freedom Diagnostics Testing) testing.
Each lot is tested by HPLC for purity, LC-MS for identity confirmation, and endotoxin assay for sterility readiness.
The lot ID is printed on every vial and ties back to a public COA library, so researchers can verify documentation before they buy and after the vial arrives.
Orders placed before 2 PM CT ship the same business day, and shipping is free on orders over $200.

References

The laboratory and preclinical research behind GHRH + GHRP secretagogues — cited for scientific context.

Eur. J. Endocrinology

Ipamorelin, the first selective growth hormone secretagogue

Raun K. et al. · 1998↗

J. Clin. Endocrinol. Metab.

A GHRH analog (CJC-1295) and sustained GH/IGF-1 elevation

Teichman S.L. et al. · 2006↗

Endocrine Reviews

Growth hormone-releasing hormone and its receptor

Mayo K.E. et al. · 1995↗

View all references+

Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. doi.org/10.1530/eje.0.1390552
Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. doi.org/10.1210/jc.2005-1536
Mayo, K. E., et al. (1995). Growth hormone-releasing hormone and its receptor. Endocrine Reviews, 16(1), 1–36. doi.org/10.1210/edrv-16-1-1

Regulatory Status

FDA, WADA anti-doping, and compounding status — provided for research context.

FDA StatusNeither component of this blend is an FDA-approved drug. CJC-1295 (modified GRF 1-29) and Ipamorelin are growth-hormone secretagogues that have not been approved by the FDA for any indication. The research-grade material supplied by Koi Peptides is synthesized independently for in vitro laboratory research only — not formulated, packaged, or labeled for human use, not equivalent to any approved or investigational drug product, and not authorized for any human or veterinary indication.

WADA Anti-Doping StatusGrowth-hormone secretagogues — including GHRH and its analogs such as CJC-1295, and growth-hormone-releasing peptides (GHRPs) such as Ipamorelin — are prohibited at all times under section S2 of the WADA Prohibited List (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Both components of this blend fall within that class, so the combination is prohibited for athletes under WADA jurisdiction, in and out of competition. There is no general Therapeutic Use Exemption for these substances.

Compounding Pharmacy StatusKoi Peptides is a chemical research supplier — not a compounding pharmacy or outsourcing facility under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act — and supplies no compounded preparations of any kind. Because neither component is an FDA-approved substance, the blend is not eligible for pharmacy compounding for human use.

Disclaimer

For research use only. Not for human or veterinary use. CJC-1295 + Ipamorelin (No DAC) is supplied to qualified research professionals for in vitro laboratory study. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Koi Research Labs LLC is a chemical supplier, not a compounding pharmacy under 503A nor an outsourcing facility under 503B of the Federal Food, Drug, and Cosmetic Act. By purchasing, the buyer agrees this material will not be introduced into humans or animals. Misuse may violate federal, state, or local laws.

Frequently Asked Questions About CJC-1295 + Ipamorelin

What is the CJC-1295 + Ipamorelin blend used for in research?+

It is the reference GHRH + GHRP dual-secretagogue combination for studying synergistic GH release on pituitary somatotrophs — pairing GHRH-receptor agonism (CJC-1295 no DAC) with ghrelin-receptor agonism (Ipamorelin) in one experimental system. Common uses include GH-release synergy experiments, cAMP and calcium-mobilization assays, and selectivity profiling against ACTH/cortisol/prolactin.

What purity is Koi’s CJC-1295 + Ipamorelin?+

Each peptide is released at ≥99% by HPLC with LC-MS-confirmed identity, against independent third-party testing covering HPLC purity, LC-MS identity, heavy metals, sterility, and endotoxin. The lot-matched COA is published in the public library against the lot number printed on the vial.

How do I reconstitute the blend?+

Use sterile or bacteriostatic water at neutral pH; add diluent slowly down the vial wall and avoid vortexing. Prepare working dilutions immediately before use, and for sterile cell-culture work filter through a 0.22 µm low-protein-binding filter. Store reconstituted material at 2 to 8 °C, or aliquot and freeze at −20 °C or below.

What is the CAS number and identity of each component?+

Ipamorelin is CAS 170851-70-4 (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, a GHRP that binds GHS-R1a). CJC-1295 (no DAC) is a modified GRF(1-29) GHRH analog that binds the GHRH receptor. Identity of both is confirmed by LC-MS on each released lot.

How should the blend be stored?+

Store the lyophilized powder at −20 °C, desiccated and protected from light; for long-term storage −80 °C is preferred. After reconstitution, store at 2 to 8 °C or aliquot and freeze. Avoid repeated freeze-thaw cycles.

Is the blend for human use?+

No. The research-grade blend supplied by Koi Peptides is for in vitro laboratory study only. Neither component is formulated, packaged, or labeled for human or veterinary use, and neither is an FDA-approved drug.

Does the blend come with a Certificate of Analysis?+

Yes. The lot-specific Certificate of Analysis is published in our public COA library and matched to the lot ID printed on the vial, covering HPLC purity, LC-MS identity, heavy metals, sterility, and endotoxin for the components from an independent independent third-party laboratory.

What does ‘No DAC’ mean?+

CJC-1295 ‘no DAC’ is the modified GRF(1-29) without the Drug-Affinity-Complex (a maleimide that binds albumin). Without DAC, the GHRH analog has a shorter-acting profile than DAC versions, which is the form used in this blend.

Reviews

There are no reviews yet.